{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T10:22:55Z","timestamp":1793701375367,"version":"4.5.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The World Health Organization (WHO) has outlined a set of targets to achieve eliminating hepatitis C by 2030. In May 2022, Lithuanian health authorities initiated a hepatitis C virus (HCV) screening program to start working towards elimination. In the program, bonus was given to general practitioners (GPs) to promote and conduct anti-HCV tests for two situations: (1) one time testing for individuals born in 1945\u20131994 and (2) annual HCV testing for persons who inject drugs or are living with human immunodeficiency virus (HIV) regardless of age. This study aimed to model the current viral hepatitis C epidemiological status in Lithuania and to outline the requirements for WHO elimination targets using the first-year HCV screening results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Individuals were invited to participate in the anti-HCV screening by GPs during routine visits. Patients who tested positive were then referred to a gastroenterologist or infectious disease doctor for further confirmatory testing. If a patient received a positive RNA test and a fibrosis staging result of \u2265\u2009F2, the doctor prescribed direct-acting antivirals. Information on the patients screened, diagnosed, and treated was obtained from the National Health Insurance Fund. The Markov disease progression model, developed by the CDA Foundation, was used to evaluate the screening program results and HCV elimination progress in Lithuania.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between May 2022 and April 2023, 790,070 individuals underwent anti-HCV testing, with 11,943 individuals (1.5%) receiving positive results. Anti-HCV seroprevalence was found to be higher among males than females, 1.9% and 1.2%, respectively. Within the risk population tested, 2087 (31.1%) seropositive individuals were identified. When comparing the screening program results to WHO elimination targets through modelling, 2180 patients still need to be treated annually until 2030, along with expanding fibrosis restrictions. If an elimination approach was implemented, 1000 new infections would be prevented, while saving 150 lives and averting 90 decompensated cirrhosis cases and 110 hepatocellular carcinoma cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>During the first year of the Lithuanian screening program, GPs were able to screen 44% of the target population. However, the country will not meet elimination targets as it currently stands without increasing treatment levels and lifting fibrosis restrictions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-024-18470-5","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T16:02:27Z","timestamp":1713196947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hepatitis C screening in Lithuania: first-year results and scenarios for achieving WHO elimination targets"],"prefix":"10.1186","volume":"24","author":[{"given":"Janina","family":"Petkevi\u010dien\u0117","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Voeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egl\u0117","family":"\u010ciupkevi\u010dien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Razavi-Shearer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Liakina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligita","family":"Jan\u010dorien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edita","family":"Kaz\u0117nait\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Via\u010deslavas","family":"Zaksas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gediminas","family":"Urbonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limas","family":"Kup\u010dinskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"18470_CR1","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","volume":"7","author":"HCV Polaris Observatory","year":"2022","unstructured":"Polaris Observatory HCV, Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7:396\u2013415.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"18470_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jvh.12875","volume":"25","author":"GV Papatheodoridis","year":"2018","unstructured":"Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, et al. Hepatitis C: the beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat. 2018;25(Suppl 1):6\u201317.","journal-title":"J Viral Hepat"},{"key":"18470_CR3","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","volume":"392","author":"GBD 2017 Causes of Death Collaborators","year":"2018","unstructured":"GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the global burden of Disease Study 2017. Lancet. 2018;392:1736\u201388.","journal-title":"Lancet"},{"key":"18470_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1055\/s-2000-9505","volume":"20","author":"HJ Alter","year":"2000","unstructured":"Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17\u201335.","journal-title":"Semin Liver Dis"},{"key":"18470_CR5","unstructured":"World Health Organization. Global Hepatitis Report 2017. https:\/\/apps.who.int\/iris\/handle\/10665\/255016. Accessed 03 December 2023."},{"key":"18470_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus Sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211\u201321.","journal-title":"N Engl J Med"},{"issue":"9956","key":"18470_CR7","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus Sofosbuvir, with or without Ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and Ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756\u201365.","journal-title":"Lancet"},{"key":"18470_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamainternmed.2015.6011","volume":"176","author":"HS Chahal","year":"2016","unstructured":"Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, et al. Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by stage of liver fibrosis in a US Treatment-Naive Population. JAMA Intern Med. 2016;176:65\u201373.","journal-title":"JAMA Intern Med"},{"key":"18470_CR9","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/jvh.12704","volume":"24","author":"M Buti","year":"2017","unstructured":"Buti M, Dom\u00ednguez-Hern\u00e1ndez R, Oyag\u00fcez I, Casado MA, Esteban R. Cost-effectiveness analysis of ledipasvir\/sofosbuvir in patients with chronic hepatitis C: treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis. J Viral Hepat. 2017;24:750\u20138.","journal-title":"J Viral Hepat"},{"key":"18470_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S2468-1253(17)30045-6","volume":"2","author":"HCV European Union","year":"2017","unstructured":"European Union HCV, Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:325\u201336.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"18470_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2018.05.027","volume":"69","author":"S Deuffic-Burban","year":"2018","unstructured":"Deuffic-Burban S, Huneau A, Verleene A, Brouard C, Pillonel J, Le Strat Y, et al. Assessing the cost-effectiveness of hepatitis C screening strategies in France. J Hepatol. 2018;69:785\u201392.","journal-title":"J Hepatol"},{"key":"18470_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1186\/s12879-019-4524-z","volume":"19","author":"C Krauth","year":"2019","unstructured":"Krauth C, Rossol S, Orts\u00e4ter G, Kautz A, Kr\u00fcger K, Herder B, et al. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies. BMC Infect Dis. 2019;19:1019.","journal-title":"BMC Infect Dis"},{"key":"18470_CR13","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.cgh.2018.08.080","volume":"17","author":"MH Eckman","year":"2019","unstructured":"Eckman MH, Ward JW, Sherman KE. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the era of Direct-Acting, Pangenotypic Treatment regimens. Clin Gastroenterol Hepatol. 2019;17:930\u2013e99.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"18470_CR14","doi-asserted-by":"publisher","first-page":"e2015756","DOI":"10.1001\/jamanetworkopen.2020.15756","volume":"3","author":"M Tatar","year":"2020","unstructured":"Tatar M, Keeshin SW, Mailliard M, Wilson FA. Cost-effectiveness of Universal and targeted Hepatitis C Virus Screening in the United States. JAMA Netw Open. 2020;3(9):e2015756.","journal-title":"JAMA Netw Open"},{"key":"18470_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/joim.12740","volume":"283","author":"S Olafsson","year":"2018","unstructured":"Olafsson S, Tyrfingsson T, Runarsdottir V, Bergmann OM, Hansdottir I, Bj\u00f6rnsson ES, et al. Treatment as Prevention for Hepatitis C (TraP hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med. 2018;283:500\u20137.","journal-title":"J Intern Med"},{"key":"18470_CR16","doi-asserted-by":"publisher","first-page":"2200952","DOI":"10.2807\/1560-7917.ES.2023.28.30.2200952","volume":"28","author":"JG Walker","year":"2023","unstructured":"Walker JG, Tskhomelidze I, Shadaker S, Tsereteli M, Handanagic S, Armstrong PA, et al. Insights from a national survey in 2021 and from modelling on progress towards hepatitis C virus elimination in the country of Georgia since 2015. Euro Surveill. 2023;28:2200952.","journal-title":"Euro Surveill"},{"key":"18470_CR17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.12659\/MSM.882511","volume":"18","author":"V Liakina","year":"2012","unstructured":"Liakina V, Valantinas J. Anti-HCV prevalence in the general population of Lithuania. Med Sci Monit. 2012;18:28\u201335.","journal-title":"Med Sci Monit"},{"issue":"6","key":"18470_CR18","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.3390\/v14061192","volume":"14","author":"E Ciupkeviciene","year":"2022","unstructured":"Ciupkeviciene E, Petkeviciene J, Sumskiene J, Dragunas G, Dabravalskis S, Kreivenaite E, et al. Hepatitis C Virus Epidemiology in Lithuania: Situation before introduction of the National Screening Programme. Viruses. 2022;14(6):1192.","journal-title":"Viruses"},{"key":"18470_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"S Blach","year":"2017","unstructured":"Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"18470_CR20","unstructured":"Population Division of the Department of Economic and Social Affairs of the United Nations. The 2019 Revision and World Urbanization Prospects: World Population Prospects. http:\/\/esa.un.org\/unpd\/wpp\/unpp\/panel_indicators.htm. Accessed 04 December 2023."},{"key":"18470_CR21","unstructured":"National Health Insurance Fund: Statistics. https:\/\/ligoniukasa.lrv.lt\/lt\/veiklos-sritys\/informacija-gydymo-istaigoms-ir-partneriams\/kompensuojamieji-vaistai-ir-medicinos-pagalbos-priemones-2\/statistika-1. Accessed 07 December 2023."},{"key":"18470_CR22","unstructured":"Lithuanian National Transplant Bureau. Statistics: transplants. https:\/\/ntb.lrv.lt\/lt\/statistika\/transplantacija\/. Accessed 07 December 2023."},{"key":"18470_CR23","first-page":"9","volume":"54","author":"K Mansberg","year":"2018","unstructured":"Mansberg K, Kull K, Salupere R, Pr\u00fckk T, Margus B, Kariis T, et al. A Population-based Surveillance Study on the Epidemiology of Hepatitis C in Estonia. Med (Kaunas). 2018;54:9.","journal-title":"Med (Kaunas)"},{"key":"18470_CR24","first-page":"532","volume":"47","author":"I Tolmane","year":"2011","unstructured":"Tolmane I, Rozentale B, Keiss J, Arsa F, Brigis G, Zvaigzne A. The prevalence of viral hepatitis C in Latvia: a population-based study. Med (Kaunas). 2011;47:532\u20135.","journal-title":"Med (Kaunas)"},{"key":"18470_CR25","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/v14030482","volume":"14","author":"R Flisiak","year":"2022","unstructured":"Flisiak R, Zar\u0119bska-Michaluk D, Ciupkeviciene E, Drazilova S, Frankova S, Grgurevic I, et al. HCV Elimination in Central Europe with Particular emphasis on microelimination in prisons. Viruses. 2022;14:482.","journal-title":"Viruses"},{"key":"18470_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","volume":"378","author":"PK Nelson","year":"2011","unstructured":"Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571\u201383.","journal-title":"Lancet"},{"issue":"12","key":"18470_CR27","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Glob Health"},{"key":"18470_CR28","first-page":"1120","volume":"57","author":"S Grubyte","year":"2021","unstructured":"Grubyte S, Urboniene J, Nedzinskiene L, Jancoriene L. The Epidemiological Patterns of Hepatitis C in Lithuania: changes in Surveillance from 2005 to 2018. Med (Kaunas). 2021;57:1120.","journal-title":"Med (Kaunas)"},{"issue":"Suppl 5","key":"18470_CR29","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/j.dld.2014.09.023","volume":"46","author":"F Negro","year":"2014","unstructured":"Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis. 2014;46(Suppl 5):S158\u201364.","journal-title":"Dig Liver Dis"},{"key":"18470_CR30","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/add.14267","volume":"113","author":"H Fraser","year":"2018","unstructured":"Fraser H, Mukandavire C, Martin NK, Goldberg D, Palmateer N, Munro A, et al. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. Addiction. 2018;113:2118\u201331.","journal-title":"Addiction"},{"key":"18470_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jtbi.2018.11.013","volume":"481","author":"AB Pitcher","year":"2019","unstructured":"Pitcher AB, Borquez A, Skaathun B, Martin NK. Mathematical modeling of hepatitis C virus (HCV) prevention among people who inject drugs: a review of the literature and insights for elimination strategies. J Theor Biol. 2019;481:194\u2013201.","journal-title":"J Theor Biol"},{"key":"18470_CR32","doi-asserted-by":"publisher","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","volume":"5","author":"S Larney","year":"2017","unstructured":"Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and Hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5:e1208\u201320.","journal-title":"Lancet Glob Health"},{"key":"18470_CR33","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/v15071413","volume":"15","author":"G Taha","year":"2023","unstructured":"Taha G, Ezra L, Abu-Freha N, Hepatitis C. Elimination: opportunities and challenges in 2023. Viruses. 2023;15:1413.","journal-title":"Viruses"},{"key":"18470_CR34","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3748\/wjg.v25.i11.1327","volume":"25","author":"I Gountas","year":"2019","unstructured":"Gountas I, Sypsa V, Papatheodoridis G, Souliotis K, Athanasakis K, Razavi H, et al. A. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. World J Gastroenterol. 2019;25:1327\u201340.","journal-title":"World J Gastroenterol"},{"key":"18470_CR35","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/jvh.13828","volume":"30","author":"E Mooneyhan","year":"2023","unstructured":"Mooneyhan E, De la Torre Rosas A, Serrano DB, Gamkrelidze I, Sanchez MJ, Kershenobich D, et al. Cost-effectiveness and economic investment to eliminate chronic hepatitis C in Mexico. J Viral Hepat. 2023;30:551\u20138.","journal-title":"J Viral Hepat"},{"key":"18470_CR36","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/liv.15584","volume":"43","author":"S Ezzat","year":"2023","unstructured":"Ezzat S, Gamkrelidze I, Osman A, Gomaa A, Roushdy A, Esmat G, et al. Impacts of the Egyptian national screening and treatment programme for viral hepatitis C: a cost-effectiveness model. Liver Int. 2023;43:1417\u201326.","journal-title":"Liver Int"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18470-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-18470-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18470-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T16:03:15Z","timestamp":1713196995000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-18470-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["18470"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-18470-5","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"assertion":[{"value":"13 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was a study based on aggregated anonymized data, which were provided by the appropriate, authorized institution, the National Health Insurance Fund under the Ministry of Health (Lithuania). The study used anonymised secondary data from government sources that could not be linked back to specific individuals, so consent to participate was not required. The study was conducted in accordance with the Declaration of Helsinki. All methods were used following relevant guidelines and regulations. The Lithuanian Bioethics Committee has confirmed that no ethical approval and informed consent was required for the study using aggregated anonymized statistical data from authorized institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1055"}}